Leaders:
Prof Paweł Kawalec (WG4 Leader)
Ms Olga Pitsillidou (WG4 Co-Leader)
Objectives:
The ultimate goal of the WG4 is to increase the awareness of the importance of the cost-effectiveness of TDM of inflammatory diseases. In addition, the WG will encompass the acceptability and affordability aspect of TDM by both patients and caregivers. To this end, experts on cost-effectiveness will be at the front line to catalyse the Action toward this essential aspect of TDM of therapeutic antibodies. WG3 will select the relevant outcomes in terms of clinical efficacy and quality of life.
This WG4 will be connected with WG2 to simulate costeffectiveness by computing absolute costs and QALYs between individualised TDM dosing and the current practice. The WG4 will also be in charge of evaluating the acceptability of TDM by patients and physicians The shared decision between the physician and patient could benefit from observance and the patient’s satisfaction with TDM.
Furthermore, patients’ preferences and empowerment are recognised as an important aspect in treatment management. Thus, WG4 will set up a research agenda on TDM acceptability and affordability by gathering both patient and caregiver perspectives. This will anticipate the hurdles for further implementation of TDM, in connection with WG5.
Tasks and activities:
- T1: Exchange knowledge about the existing cost-effectiveness studies of TDM.
- T2: Create a framework and health economic model for the international evaluation of cost-effectiveness of TDM.
- T3: Educate health authorities, physicians, and patients about the importance of TDM and its costeffectiveness evaluation.
- T4: Exchange knowledge about existing patients’ preferences and empowerment studies in the context of chronic inflammatory diseases.
- T5: Perform quantitative and qualitative studies (i.e., revealed preference methods), with the support of European patient associations (clinicians, nurses, pharmacists) to tackle patients’ expectations and preferences.
- T6: Create a round table on patients’ preferences and empowerment of TDM, gathering patients and care providers (clinicians, nurses, pharmacists).
- T7: Inform health authorities, educate physicians and patients about the importance of patients’ preferences and empowerment in the field of chronic inflammatory diseases.
Deliverables:
- D1: Publication of systematic literature review on cost-effectiveness of TDM of therapeutic antibodies in inflammatory diseases.
- D2: Identification of outcomes pertaining to cost-effectiveness, disease activity score, and quality of life that could be used for cost-effectiveness analyses.
- D3: Publication of guidelines on how to perform an effective cost-effectiveness study of TDM.
- D4: Publication of a perspective paper on acceptability and affordability of TDM of therapeutic antibodies in chronic inflammatory diseases.
- D5: Publication of patients’ preferences and empowerment round table on TDM of therapeutic antibodies.